Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fortress Biotech (FBIO) EBT Margin: 2013-2025

Historic EBT Margin for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to 50.21%.

  • Fortress Biotech's EBT Margin rose 23221.00% to 50.21% in Q3 2025 from the same period last year, while for Sep 2025 it was -120.06%, marking a year-over-year increase of 6908.00%. This contributed to the annual value of -209.00% for FY2024, which is 2722.00% down from last year.
  • As of Q3 2025, Fortress Biotech's EBT Margin stood at 50.21%, which was up 122.99% from -218.43% recorded in Q2 2025.
  • Fortress Biotech's EBT Margin's 5-year high stood at 50.21% during Q3 2025, with a 5-year trough of -465.29% in Q1 2023.
  • For the 3-year period, Fortress Biotech's EBT Margin averaged around -188.06%, with its median value being -182.00% (2024).
  • Over the last 5 years, Fortress Biotech's EBT Margin had its largest YoY gain of 29,058bps in 2023, and its largest YoY loss of 26,831bps in 2023.
  • Quarterly analysis of 5 years shows Fortress Biotech's EBT Margin stood at -338.46% in 2021, then plummeted by 899bps to -347.45% in 2022, then soared by 20,404bps to -143.41% in 2023, then slumped by 2,841bps to -171.82% in 2024, then skyrocketed by 23,221bps to 50.21% in 2025.
  • Its EBT Margin was 50.21% in Q3 2025, compared to -218.43% in Q2 2025 and -166.12% in Q1 2025.